Cost-effectiveness analysis of lapatinib plus capecitabine versus capecitabine alone in the second line treatment for breast cancer treatment

被引：0
|
作者：
Ejzykowicz, F. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70201-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A60 / A61
页数：2
相关论文
共 50 条
  • [31] Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer
    Sherrill, B.
    Amonkar, M. M.
    Stein, S.
    Walker, M.
    Geyer, C.
    Cameron, D.
    BRITISH JOURNAL OF CANCER, 2008, 99 (05) : 711 - 715
  • [32] Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer
    B Sherrill
    M M Amonkar
    S Stein
    M Walker
    C Geyer
    D Cameron
    British Journal of Cancer, 2008, 99 : 711 - 715
  • [33] Cost-effectiveness of lapatinib plus capecitabine in women with HER2+metastatic breast cancer who have received prior therapy with trastuzumab
    Delea, Thomas E.
    Tappenden, Paul
    Sofrygin, Oleg
    Browning, Dominy
    Amonkar, Mayur M.
    Karnon, Jon
    Walker, Mel D.
    Cameron, David
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2012, 13 (05): : 589 - 603
  • [34] A phase II study of lapatinib and capecitabine in second line treatment of locally advanced/metastatic pancreatic cancer
    He, A. R.
    Hwang, J. J.
    Marshall, J.
    Pishvaian, M.
    Slack, R.
    Weiner, L. M.
    Wellstein, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB plus DOCETAXEL VERSUS DOCETAXEL ALONE IN THE TREATMENT OF HER2+METASTATIC BREAST CANCER
    Athanasakis, K.
    Golna, C.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [36] Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
    Vakaramoko Diaby
    Georges Adunlin
    Simon B. Zeichner
    Kiran Avancha
    Gilberto Lopes
    Stefan Gluck
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2014, 147 : 433 - 441
  • [37] Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer
    Wu, Qiuji
    Wang, Xinyuan
    Zhang, Mengxi
    Liao, Weiting
    Wang, Feng
    Li, Qiu
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (04) : 153 - 159
  • [38] Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
    Thomas E. Delea
    Paul Tappenden
    Oleg Sofrygin
    Dominy Browning
    Mayur M. Amonkar
    Jon Karnon
    Mel D. Walker
    David Cameron
    The European Journal of Health Economics, 2012, 13 : 589 - 603
  • [39] Cost-effectiveness of taxanes as second line agents in treatment of metastatic breast cancer
    Kawatkar, AA
    Hay, JW
    VALUE IN HEALTH, 2006, 9 (03) : A108 - A108
  • [40] COST-EFFECTIVENESS ANALYSIS OF FULVESTRANT IN THE TREATMENT OF METASTATIC BREAST CANCER IN SECOND-LINE CHEMOTHERAPY
    Krysanov, I
    Krysanova, V
    VALUE IN HEALTH, 2014, 17 (07) : A637 - A637
12345